4.7 Article

Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 77, 期 7, 页码 1916-1922

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkac108

关键词

-

资金

  1. Wockhardt

向作者/读者索取更多资源

The study found that combinations of PBP3-active beta-lactams with DBOs like zidebactam remain active against many MBL producers, but this activity is influenced by inoculum levels. MIC values for MBL producers were strongly dependent on inoculum, while non-MBL isolates showed less dependence on inoculum levels.
Objectives Combinations of PBP3-active beta-lactams with developmental diazabicyclooctanes (DBOs), e.g. zidebactam, remain active against many MBL producers via an enhancer effect. We explored how this activity is affected by inoculum. Materials and methods MICs of zidebactam and its cefepime and ertapenem combinations (WCK 5222 and WCK 6777, respectively) were determined by BSAC agar dilution at inocula from 3-6 x 10(3) to 3-6 x 10(5) cfu/spot. Isolates, principally Klebsiella spp., were chosen as having previously tested resistant to zidebactam or its cefepime combination, and by beta-lactamase type. Results MICs of zidebactam, tested alone, were strongly inoculum dependent regardless of beta-lactamase type; MICs of its cefepime and ertapenem combinations likewise were strongly inoculum dependent-rising >= 32-fold across the inoculum range tested-but only for MBL producers. Combination MICs for isolates with non-MBLs, including those with OXA-48 (where the enhancer effect remains critical for ertapenem/zidebactam) were much less inoculum dependent, particularly for cefepime/zidebactam. MBL producers frequently moved between putative 'susceptible' (MIC <= 8 + 8 mg/L) and 'resistant' (MIC > 8 + 8 mg/L) categories according to whether the inoculum was at the high or low end of BSAC's acceptable (1-4 x 10(4) cfu/spot) range. Conclusions The activity of zidebactam combinations against MBL producers, which strongly depends on the enhancer effect, is inoculum dependent. Animal data suggest consistent in vivo activity even in high-inoculum pneumonia models. Contingent on this being supported by clinical experience, the combination behaviour may be best represented by the MICs obtained at the lower end of BSAC's inoculum range.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据